Clinical trial
A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q)
NCT01556477 is registered in ClinicalTrials.gov with Nordic MDS Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q)
- Lead sponsor
- Nordic MDS Group
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2012
- Completion date
- November 30, 2014
- Enrollment
- 72 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myelogenous leukemia, myelodysplastic syndrome